Skip Menu
Click on the (+) below for a short summary of each Investigators area of research interest and expertise:
Expand All Collapse All
  • Clark, Shannon
    Clark

    Shannon M. Clark MD
    Professor
    Obstetrics and Gynecology

    I am the primary investigator for The Obstetric-Fetal Pharmacology Research Center (OPRC) Network, sponsored by the NICHD and focuses on pharmacologic outcomes in pregnant women. I am interested in maternal disease, fetal abnormalities and pharmacology in pregnancy.   Research
  • Nanovskaya, Tatiana
    T_Nanovskaya

    Tatiana Nanovskaya PhD
    Associate Professor
    Obstetrics and Gynecology

    Our goal for the investigation is to examine the preliminary safety and efficacy of bupropion sustained release (SR) to help pregnant women stop smoking. We are determining whether bupropion SR reduces cigarette craving and withdrawal symptoms during pregnancy. This research is necessary for the development of medications to treat pregnant smokers. Research
  • Rytting, Erik
    Dr Rytting

    Erik Rytting PhD
    Associate Professor
    Obstetrics and Gynecology

    Our research seeks to improve therapeutic options when medication must be administered during pregnancy.  This includes understanding drug transfer across the placenta, pharmacokinetic studies to predict appropriate doses, and the development of nanomedicine for targeted drug delivery.  Research
  • Wang, Xiao-Ming
    Dr Wang

    Xiao-ming wang PhD, MS
    Assistant Professor
    Obstetrics and Gynecology

    Our research seeks to improve therapeutic options when medication must be administered during pregnancy. This includes understanding drug transfer across the placenta, pharmacokinetic studies to predict appropriate doses, and the development of nanomedicine for targeted drug delivery.  Research

Maternal-Fetal Pharmacology and Bio-Drug Development Research

Director: Mahmoud Ahmed PhD

The Department of Obstetrics & Gynecology has a long history of encouraging physician-scientists to participate in clinical studies to continually improve the health outcomes for women and their infants at UTMB and across the word. Many of our clinicians participate in studies funded by governmental, industry, and private agencies, with an eye to determining risk factors during pregnancy, as well as establishing safe evidence-based treatments for women during pregnancy.

Our research focuses on pharmacologic outcomes in pregnant women. The study of drugs used during pregnancy is one of the most neglected areas in clinical pharmacology and drug research. The lack of Food and Drug Administration obstetric labeling and the universal off-label use of drugs in pregnancy are the direct result of the inadequacy of research and clinical trials of drugs in this special population. A major goal of this program is to identify, characterize, and study those drugs that are of therapeutic value during pregnancy and whose clinical pharmacology (both pharmacokinetics and pharmacodynamics) is altered by the pregnant state in normal or abnormal pregnancies. We also serves as a UTMB resource for training health professionals in obstetric-fetal pharmacology and drug trials in pregnant women.